phone icon  Int'l : +1-503-894-6022
Allied Market Research
0
Shopping Cart is Empty..
$ 0

Recent progress in biological therapies has widened the scale of therapeutic targets for treatment of cancer with the identification of tumor cell specific genes. Immunotherapies/ biologics are emerging as potential therapies to find the permanent cure for various cancer types. Amongst various biologics, drugs based on monoclonal antibodies (mAbs) have gained significant attention in recent years due to their high efficacy. Global cancer drugs market accounted for $78,238.9 million in 2015, and is forecast to generate revenue of $111,938.4 million by 2020. The cancer drugs market is driven by the growing prevalence of various types of cancer, increasing demand of biological and targeted drug therapies, continuous patent expiry of key cancer drugs and the rising impact of biosimilars. However, the high cost of drug development, the threat of failure and the adverse effects of cancer drug therapy, particularly chemotherapy, hinders the market growth. Developed nations have implemented strict regulations for the design and development of cancer drugs. USFDA and European Union have undertaken significant initiatives to fuel the growth of the cancer drugs market by providing pre-market approval for potential drugs under clinical development. Asia-Pacific and LAMEA are promising regions for conducting clinical trials due a large population base and the low cost of clinical trials as compared to North America and Europe. Nevertheless, advancement of cancer drug research owing to biological/targeted therapies and personalized medicines hold promising opportunities for pharmaceutical, bio-pharmaceutical and biotechnology companies engaged in developing cancer drugs.

Market Segment Review:

The competitive structure of the global cancer drugs market is analyzed using Porter’s Five Forces Model. According to Porter’s analysis, the bargaining power of buyers is low due high cost of drugs, lesser knowledge about the products/drugs. However, the bargaining power of suppliers tends to moderate owing to their lower concentration and requirement of higher capital investment. Cancer drugs are mostly protected with IPR rights thus, leads to increase in the barriers for new entrants. 

Global cancer drugs market by therapeutic modalities is segmented into chemotherapy, Targeted therapy, Immunotherapy, Hormonal therapy and others. Immunotherapy dominates the global market for cancer drugs due to its high efficacy and less side effects. Monoclonal antibodies such as trastuzumab, bevacizumab and rituximab are potential immunotherapeutic agents that have achieved magnanimous sales. The cancer immunotherapy market is primarily driven by huge research investments from multinational companies along with research collaborations for the development of cancer immunotherapeutics. Over the past few years, targeted cancer therapies have gained significant attention due to their tumor cell specific action in protecting healthy cells from the toxic effects of cancer drugs. 

Global cancer drugs market by cancer type is segmented into Blood cancer, Breast cancer, gastrointestinal tract cancer, Prostate cancer, Lung Cancer, Skin Cancer and other cancer. Amongst these different cancer types, blood cancer was the largest revenue generating segment in 2015. The growth of blood cancer segment is majorly due to the high cost of the drugs used to treat blood cancer. The prevalence of blood cancer is less in developed nations, however, the diagnosis rate is more than 90% and almost every person diagnosed with blood cancer seeks complete treatment for the cure of blood cancer. Due to the high disposable incomes of consumers in developed nations, expensive drug therapy of blood cancer is affordable in these regions. Majority of the recently evolved biologics (drugs based on monoclonal antibodies) showed a significant cure for blood cancer; therefore, usage rate of these drug is high, despite of their high cost. 

Geographic Review:

Geographically, the Global cancer drugs market segments into North America, Europe, Asia-Pacific and LAMEA. North America dominates the market for cancer drugs as the region houses companies engaged in the development of cancer drugs. Additionally, the disposable incomes of consumers and health insurance cover for life-threatening diseases in North America are very high which increases the affordability of cancer treatment. In recent years, US Food and Drug Administration (USFDA) has taken initiatives to support the growth of cancer drugs market by providing pre-market approval to the drugs, which are in the clinical phase; thus, accelerating the clinical development. 

A large number of patents in North America indicate substantial investment in R&D from multinational companies as well as research organizations. Europe is the second largest market for cancer drugs and is expected to grow at a CAGR of 6.8% during the analysis period. In North America and Europe, a majority of the multinational players have focused on the development of biologics or immunotherapeutic owing to its high efficacy and target specific action. The research for cancer drugs in Asia-Pacific and LAMEA is emerging with the focus towards the development of biosimilars. The prevalence of various cancer types is high in developing countries which render these regions as promising locations to conduct clinical trials. Moreover, the cost of clinical research is low in these regions due to the availability of a huge population base and favourable government policies. 

Japan Oncology/Cancer Drugs Market Review:

Japan has largest share to the total Asia Pacific cancer drug market due to the high prevalence of cancer in Japanese population. Lung cancer is the major cause of death in Japanese population. The total healthcare expenditure of japan was $495 billion in 2013. 

Several new drugs are now approved in Japan, including Afinitor, Avastin, Jevtana, Sutent and Zytiga, which could trigger a growth of cancer drug market and a shift in the treatment paradigm in the foreseen future.

Access to new drugs might be delayed in Japan due to strict regulatory processes in Japan. Pharmaceutical and Medical Devices Agency (PMDA) and Ministry of Health, Labor and Welfare (MHLW), are the regulatory agencies in Japan. Jevtana (Cabazitaxel acetonate) and MabCampath (Alemtuzumab), by Sanofi, are recently approved cancer drugs in Japan.

Japanese government health insurance is the most generous in Asia and offers the highest rates of reimbursement. The government offers coverage for approved treatments, including treatments for cancer, to all citizens. The treatments are eligible for coverage as long as they are approved by Japan’s MHLW.

Japan oncology/cancer drugs market by therapeutic modalities, 2020 

Japan oncology cancer drugs market by therapeutic modalities 2020

Competitive Review:

The key players profiled in this report include Amgen Inc., Johnson & Johnson, GlaxoSmithKline, Eli lilly & Co., Roche diagnostics, Novartis AG, Pfizer, Merck & Co., Sanofi, and Celgene Corporation. Roche, Novartis and Celgene are the top three players in Global cancer drugs market with a wide of cancer product portfolio. The three companies contribute to ~60% of the total market share. The immunotherapeutics developed by Roche namely Rituxan, Avastin and Herceptin achieved blockbuster sales in 2013. A majority of the cancer drug manufacturers have adopted collaboration, approval and acquisition as their key developmental strategies to achieve a competitive edge. Moreover, companies are forming strategic alliances to accelerate their clinical developments. These strategies have proved to be effective in helping key players retain their leading positions in the global market.

Global-Oncology_Cancer-Drugs-Market-Sidebar

ONCOLOGY DRUGS MARKETKEY BENEFITS

  • The report provides the quantitative analysis of the current trends, size and estimations for the forecast period 2013-2020 that assists in identifying the prevailing opportunities to capitalize on
  • The report helps in understanding the strategies adopted by various companies for consolidating their positions in the industry.
  • The report provides comprehensive analysis of factors that drive and restrict the growth of the cancer drugs market
  • Demand and supply conditions of cancer drugs across all geographic regions are comprehensively analyzed
  • Competitive intelligence (of leading manufacturers) helps in understanding the competitive market scenario and opportunities across the geographies
  • SWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companies

ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION

The Oncology drugs market is segmented by the therapeutic modalities, cancer types and geography.

BY THERAPEUTIC MODALITIES

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Others

BY CANCER TYPES

  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Respiratory/Lung Cancer
  • Skin Cancer
  • Other Cancers

BY GEOGRAPHY

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Others
  • Asia-Pacific
    • India
    • China
    • Japan
    • Australia
    • Others
  • LAMEA
    • GCC (Gulf Corporation Council)
    • Others
* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Title/ Chapter Name

Chapter: 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 Market beyond what to expect by 2025

2.1.1 Moderate growth scenario
2.1.2 Rapid growth scenario
2.1.3 Diminishing growth scenario

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Development of novel immuno-oncology drug products
3.3 Key findings

3.3.1 Top Factors impacting oncology drugs market
3.3.2 Top investment pockets of oncology drugs market
3.3.3 Top winning strategies of oncology drugs market

3.4 Porters five forces analysis

3.4.1 Bargaining power of buyers (low)
3.4.2 Bargaining power of suppliers (moderate)
3.4.3 Threat of new entrants (Low)
3.4.4 Threat of substitutes (moderate)
3.4.5 Intense competitive rivalry

3.5 Value chain analysis

3.5.1 Primary activities
3.5.2 Support activities

3.6 Government regulations and reimbursement

3.6.1 Regulations in United States
3.6.2 Regulations in Europe
3.6.3 Regulations in Asia-Pacific
3.6.4 Reimbursement scenario

3.7 Patent analysis

3.7.1 Patent Analysis by type of patents
3.7.2 Patent analysis by geography

3.8 Market share analysis, 2013
3.9 Clinical trials for oncology drugs
3.10 Market dynamics

3.10.1 Drivers

3.10.1.1 Rising incidence and prevalence of various cancer types
3.10.1.2 Growing importance of biological and targeted drug therapies
3.10.1.3 Expiration of key patents and biosimilars impact
3.10.1.4 Acquisitions and collaborations bolt-on strategies driving the market growth

3.10.2 Restraints

3.10.2.1 High cost of drug development and threat of failure
3.10.2.2 Adverse effects of anti-cancer drug therapy

3.10.3 Opportunities

3.10.3.1 Advancement of anti-cancer drugs research
3.10.3.2 Personalized medicine approach

Chapter: 4 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES

4.1 Chemotherapy

4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast

4.2 Targeted therapy

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 Immunotherapy (biologics therapy)

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 Hormonal therapy

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast

4.5 Others

4.5.1 Market size and forecast

Chapter: 5 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER TYPES

5.1 Blood cancer

5.1.1 Epidemiology prevalence and incidence
5.1.2 Trends in blood cancer treatment
5.1.3 Market size and forecast

5.2 Breast cancer

5.2.1 Epidemiology prevalence and incidence
5.2.2 Trends in breast cancer treatment
5.2.3 Market size and forecast

5.3 Gastrointestinal cancer

5.3.1 Epidemiology prevalence and incidence
5.3.2 Trends in treatment of gastrointestinal cancer
5.3.3 Market size and forecast

5.4 Prostate cancer

5.4.1 Epidemiology prevalence and incidence
5.4.2 Trends in treatment of prostate cancer
5.4.3 Market size and forecast

5.5 Respiratory/lung cancer

5.5.1 Epidemiology prevalence and incidence
5.5.2 Trends in treatment of lung Cancer
5.5.3 Market size and forecast

5.6 Skin cancer

5.6.1 Epidemiology prevalence and incidence
5.6.2 Trends in treatment of skin cancer
5.6.3 Market size and forecast

5.7 Other cancers

5.7.1 Trends in treatment of other cancer types

Chapter: 6 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY

6.1 North America

6.1.1 Market size and forecast
6.1.2 United States

6.1.2.1 Key market trends
6.1.2.2 Market size and forecast

6.1.3 Canada

6.1.3.1 Key market trends
6.1.3.2 Market size and forecast

6.1.4 Mexico

6.1.4.1 Market size and forecast

6.2 Europe

6.2.1 Key market trends
6.2.2 Market size and forecast
6.2.3 Germany

6.2.3.1 Key market trends
6.2.3.2 Market size and forecast

6.2.4 France

6.2.4.1 Key market trends
6.2.4.2 Market size and forecast

6.2.5 United Kingdom

6.2.5.1 Key market trends
6.2.5.2 Market size and forecast

6.2.6 Others

6.2.6.1 Key market trends
6.2.6.2 Market size and forecast

6.3 Asia Pacific

6.3.1 Key market trends

6.3.1.1 Market size and forecast

6.3.2 India

6.3.2.1 Key market trends
6.3.2.2 Market size and forecast

6.3.3 China

6.3.3.1 Key market trends
6.3.3.2 Market size and forecast

6.3.4 Japan

6.3.4.1 Key market trends
6.3.4.2 Market size and forecast

6.3.5 Australia

6.3.5.1 Key market trends
6.3.5.2 Market size and forecast

6.3.6 Others

6.4 LAMEA

6.4.1 GCC (gulf corporation council)

6.4.1.1 Key Market Trends
6.4.1.2 Market size and forecast

6.4.2 Others

6.4.2.1 Market size and forecast

Chapter: 7 COMPANY PROFILES

7.1 Amgen Inc.

7.1.1 Company overview
7.1.2 Amgen Inc. snapshot
7.1.3 Financial performance
7.1.4 Operating business segment overview
7.1.5 Key strategies and development
7.1.6 SWOT analysis

7.2 Johnson and Johnson

7.2.1 Company overview
7.2.2 Johnson & Johnson snapshot
7.2.3 Operating business segment overview
7.2.4 Financial performance
7.2.5 Key strategies moves and development
7.2.6 SWOT Analysis

7.3 Roche Diagnostics

7.3.1 Company overview
7.3.2 Roche Diagnostics snapshot
7.3.3 Operating business segment overview
7.3.4 Financial performance
7.3.5 Key strategies moves and development
7.3.6 SWOT analysis

7.4 GlaxoSmithKline PLC

7.4.1 Company overview
7.4.2 GlaxoSmithKline PLC Snapshot
7.4.3 Operating business segment overview
7.4.4 Financial performance
7.4.5 Key strategies move and development
7.4.6 SWOT Analysis of GlaxoSmithKline PLC

7.5 Merck & Company

7.5.1 Company overview
7.5.2 Merck & Company snapshot
7.5.3 Operating business segment overview
7.5.4 Financial performance
7.5.5 Key strategies move and development
7.5.6 SWOT analysis

7.6 Novartis AG

7.6.1 Company overview
7.6.2 Novartis AG snapshot
7.6.3 Operating business segment overview
7.6.4 Financial performance
7.6.5 Key strategies move and development
7.6.6 SWOT analysis

7.7 Pfizer

7.7.1 Company overview
7.7.2 Pfizer snapshot
7.7.3 Operating business segment overview
7.7.4 Financial performance
7.7.5 Key strategies move and development
7.7.6 SWOT analysis

7.8 Sanofi

7.8.1 Company overview
7.8.2 Sanofi snapshots
7.8.3 Operating business segment overview
7.8.4 Financial performance
7.8.5 Key strategies move and development
7.8.6 SWOT analysis

7.9 Eli Lilly and Company

7.9.1 Company overview
7.9.2 Eli Lilly and company snapshots
7.9.3 Operating business segment overview
7.9.4 Financial performance
7.9.5 Key strategies move and development
7.9.6 SWOT analysis

7.10 Celgene Corporation

7.10.1 Company overview
7.10.2 Celgene corporation snapshots
7.10.3 Operating business segment overview
7.10.4 Financial performance
7.10.5 Key strategies move and development
7.10.6 SWOT analysis

LIST OF TABLES

TABLE 1 MODERATE GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 2025, ($MILLION)
TABLE 2 RAPID GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 2025, ($MILLION)
TABLE 3 DIMINISHING GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 2025, ($MILLION)
TABLE 4 APPLICABLE STANDARDS FOR THE UNITED STATES ANTICANCER DRUG DEVELOPMENT PROCESS
TABLE 5 INTERNATIONAL DISEASE CLASSIFICATION CODES AND DESCRIPTION OF CANCER DIAGNOSES
TABLE 6 CLINICAL LABORATORY FEE SCHEDULE (CLFS) REIMBURSEMENT CODES
TABLE 7 CLINICAL TRIALS FOR ONCOLOGY DRUGS
TABLE 8 WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES, (EXCLUDING NON-MELANOMA SKIN CANCER) (2012)
TABLE 9 LIST OF BIOLOGICAL AND TARGETED DRUGS WITH THEIR REVENUE IN 2013 ($MILLION)
TABLE 10 LIST OF KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES
TABLE 11 LIST OF COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF ANTI-CANCER DRUGS
TABLE 12 GLOBAL ONCOLOGYDRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 13 GLOBAL CHEMOTHERAPY DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 14 GLOBAL TARGETED THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 15 CANCER IMMUNOTHERAPEUTICS AND THEIR CUMULATIVE PRICES
TABLE 16 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 17 GLOBAL HORMONAL THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 18 GLOBAL OTHER THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 19 GLOBAL ONCOLOGYDRUGS MARKET BY CANCER TYPES, 2013 2020 ($MILLION)
TABLE 20 INCIDENCE AND PREVALENCE OF BLOOD CANCER TYPES IN UNITED STATES
TABLE 21 USFDA APPROVED DRUGS FOR THE TREATMENT OF BLOOD CANCERS
TABLE 22 GLOBAL BLOOD CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 23 WORLDWIDE INCIDENCE AND PREVALENCE OF BREAST CANCER (2012)
TABLE 24 GLOBAL BREAST CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 25 WORLDWIDE INCIDENCE AND PREVALENCE OF GASTROINTESTINAL CANCER (2012)
TABLE 26 GLOBAL GASTROINTESTINAL CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 27 WORLDWIDE INCIDENCE AND PREVALENCE OF PROSTATE CANCER (2012)
TABLE 28 DRUGS USED IN PROSTATE CANCER AND THEIR REVENUE (2013)
TABLE 29 GLOBAL PROSTATE CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 30 WORLDWIDE INCIDENCE AND PREVALENCE OF LUNG CANCER (2012)
TABLE 31 LIST OF NEW THERAPEUTIC AGENTS FOR LUNG CANCER TREATMENT
TABLE 32 GLOBAL RESPIRATORY/LUNG CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 33 GLOBAL SKIN CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 34 WORLDWIDE INCIDENCE AND PREVALENCE OF CERVICAL CANCER (2012)
TABLE 35 GLOBAL OTHER CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 36 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 37 NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 38 COSTS PER THERAPY OF THE COMMON CANCER DRUGS IN THE UNITED STATES:
TABLE 39 UNITED STATES ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 40 CANADA ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 41 MEXICO ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 42 NEW ANTICANCER DRUGS APPROVED BY E MA 2013
TABLE 43 EUROPE ONCOLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 2020 ($MILLION)
TABLE 44 GERMANY ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 45 FRANCE ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 46 UNITED KINGDOM ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 47 OTHERS ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 48 ASIA PACIFIC ONCOLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 2020 ($MILLION)
TABLE 49 INDIA ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 50 CHINA ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 51 JAPAN ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 52 AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 53 OTHERS ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 54 LAMEA ONCOLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 2020 ($MILLION)
TABLE 55 GCC ONCOLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 2020 ($MILLION)
TABLE 56 LATIN AMERICAN/ AFRICAN COUNTRIES AND THEIR PRICING POLICIES FOR CANCER THERAPIES
TABLE 57 OTHERS
CANCER/ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 58 AMGEN INC. SNAPSHOT
TABLE 59 JOHNSON & JOHNSON SNAPSHOT
TABLE 60 JOHNSON AND JOHNSON OPERATING SEGEMENTS
TABLE 61 ROCHE DIAGNOSTICS SNAPSHOT
TABLE 62 ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 63 GLAXOSMITHKLINE PLC SNAPSHOT
TABLE 64 GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
TABLE 65 MERCK & COMPANY SNAPSHOT
TABLE 66 MERCK & CO. OPERATING SEGEMENTS
TABLE 67 NOVARTIS AG SNAPSHOT
TABLE 68 NOVARTIS AG OPERATING SEGEMENTS
TABLE 69 PFIZER SNAPSHOT
TABLE 70 PFIZER OPERATING SEGEMENTS
TABLE 71 SANOFI SNAPSHOTS
TABLE 72 SANOFI OPERATING SEGEMENTS
TABLE 73 ELI LILLY AND COMPANY SNAPSHOTS
TABLE 74 ELI LILLY AND COMPANY OPERATING SEGEMENTS
TABLE 75 CELGENE CORPORATION SNAPSHOTS

LIST OF FIGURES

FIG. 1 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN MODERATE GROWTH SCENARIO
FIG. 2 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN RAPID GROWTH SCENARIO
FIG. 3 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN DIMINISHING GROWTH SCENARIO
FIG. 4 TOP FACTORS IMPACTING ONCOLOGY DRUGS MARKET (2014-2020)
FIG. 5 TOP INVESTMENT POCKETS OF ONCOLOGY DRUGS MARKET (2013)
FIG. 6 TOP WINNING STRATEGIES FOR GLOBAL ONCOLOGY DRUG MARKET (2011-2013)
FIG. 7 TOP WINNING STRATEGIRS BY SUBTYPE
FIG. 8 PORTERS FIVE FORCES ANALYSIS OF ONCOLOGY DRUGS MARKET
FIG. 9 VALUE CHAIN ANALYSIS OF GLOBAL CANCER DRUGS MARKET
FIG. 10 PATENT ANALYSIS BY TYPE OF PATENTS (2011-2015)
FIG. 11 PATENT ANALYSIS BY GEOGRAPHY (2011-2015)
FIG. 12 MARKET SHARE ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET (2013)
FIG. 13 PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 14 AMGEN INC. REVENUE BY GEOGRAPHY (2013)
FIG. 15 AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2013)
FIG. 16 SWOT ANALYSIS OF AMGEN INC.
FIG. 17 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2013)
FIG. 18 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS (2013)
FIG. 19 SWOT ANALYSIS OF JOHNSON & JOHNSON
FIG. 20 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 21 ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
FIG. 22 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 23 GLAXOSMITHKLINE PLC REVENUE BY GEOGRAPHY (2013)
FIG. 24 GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 25 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
FIG. 26 MERCK & CO. REVENUE BY GEOGRAPHY (2013)
FIG. 27 MERCK & CO. REVENUE BY BUSINESS UNITS (2013)
FIG. 28 SWOT ANALYSIS OF MERCK & COMPANY
FIG. 29 NOVARTIS AG REVENUE BY GEOGRAPHY (2013)
FIG. 30 NOVARTIS AG REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 31 SWOT ANALYSIS OF NOVARTIS AG
FIG. 32 PFIZER REVENUE BY GEOGRAPHY (2013)
FIG. 33 PFIZER REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 34 SWOT ANALYSIS OF PFIZER
FIG. 35 SANOFI REVENUE BY GEOGRAPHIES (2013)
FIG. 36 SANOFI REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 37 SWOT ANALYSIS OF SANOFI
FIG. 38 ELI LILLY AND COMPANY REVENUE BY GEOGRAPHIES (2013)
FIG. 39 ELI LILLY AND COMPANY REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 40 SWOT ANALYSIS OF ELI LILLY AND COMAPANY
FIG. 41 CELGENE CORPORATION REVENUE BY GEOGRAPHIES (2013)
FIG. 42 CELEGENE CORPORATION REVENUE BY PRODUCT SALES (2013)
FIG. 43 SWOT ANALYSIS OF CELGENE CORPORATION

Recent progress in targeted and biological/immunotherapies has widened the scale of therapeutic targets for the treatment of cancer by identifying tumor cell specific genes. Immunotherapies/ biologics are emerging as potent therapies to find the permanent cure from the various types of cancer. Amongst various biologics, cancer drugs market that relies on monoclonal antibodies (mAbs) have gained significant attention from pharmaceutical companies owing to high efficacy. Adjuvant application of monoclonal antibodies (mAbs) with chemotherapy has provided competitive edge for pharmaceutical companies. Therefore, development of new biological therapies for treating cancer or widening the applications of existing immunotherapeutics to cover various cancer types offers tremendous growth opportunities for manufacturers in cancer drugs market. 

Additionally, personalized medicines could also be the promising approach to find the suitable treatment solution for cancer, based on individual’s genetic makeup and their tumour biology. This approach in oncology drugs market is vital in the manufacturing of oncology drugs and could be well executed by using targeted treatments and pharmacogenomics principles that produces significant results for the cure of cancer. Despite of the excitement that personalized medicines has created, very little is known about genetic changes that occur in a malignant cell. Therefore, it is complex to develop the personalized cancer medicine. Further research in oncology drugs market especially personalized medicines approach could be highly fruitful to find the effective treatment solutions to various cancer types.

Patent expiration for the key cancer drugs has significantly increased the scope of economic biosimilar across developing regions, where the prevalence of cancer is at peak. Moreover, the migration of pharmaceutical companies in pharmerging economies such as China, India, and Brazil owing to presence of low cost labor, and less stringent government regulations has reduced the cost of cancer drugs. 

 

SINGLE USER
GROUP LICENSE
SITE LICENSE
GLOBAL LICENSE
$4515
$5325
$7350
$10680
LICENSE INFO
Users/Sharing
Restricted to one authorized user

Limited to 5 authorized users

Up to 25 users


unlimited within company / enterprise
Copy/Paste
Allowed up to 20% of the content
Allowed up to 25% of the content
Allowed up to 50% of the content
allowed 100%

Printing
One print only

Five Prints

Unlimited for internal use
Unlimited for internal use
Delivery Formats
ADDED BENIFITS
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
MULTIPLE PURCHASE
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
connect
Need to add more ?
request

Single User
$4515
Group User
$5325
Site User
$7350
Global User
$10680
buy now

Discount will be applied in cart.
First time buyer ?
Check offers and discount
on this report
GET DISCOUNT
Need More Information
phone_n +1-503-894-6022

Help AMR help@alliedmarketresearch.com
Or
Send Enquiry
WHY ALLIED MARKET RESEARCH?
Infallible Methodology
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader
RECENTLY VIEWED REPORTS
get_n
SIMILAR MARKET REPORTS
  • ...
    In-vitro fertilization is a type of assisted reproductive technology that helps women in conceiving. The global IVF market was valued at $9.3 billion in 2012 and is expected to grow up to $21.6 billion by 2020. Delayed pregnancy in women is one of the major driving factors of the IVF market, as the chances of conceiving lowers with age. The pregnancy success rate with IVF technique is higher in the age group of 35-39.Globally, the number of couples with infertility issues was found to be 48.5 million in 2010.
    Jan 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    One of the key reasons for adoption of flow cytometry technology is its precise deliverance of results comparing to conventional methods such as ELISA. The emergence of this technology as one of the leading applications has brought various advancements in the diagnosis of diseases such as HIV and cancer as well as in research fields. With rising advancements in information technology, it finds application in drug discovery and development. Moreover, it is now used in hematopoietic stem cell research, multiparameter analysis and pharmacogenesis.
    Dec 2013 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    A hernia is a type of disease in which the inner layers of abdominal muscle become weakened and the lining of the abdomen then bulges out into a small sac. Hernias can occur in several places, such as the navel (umbilical hernia), groin (inguinal hernia), and at the incision site of surgery (post-surgery hernia). Hernia can be treated in two ways, i.e. watchful waiting and surgical procedures.
    Feb 2015 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
ON DEMAND REPORTS
  • ...
    In order to thwart microbial growth and render the product contamination free, packaging plays a vital role and serves the purpose of safety throughout the shelf life of pharmaceuticals. In regulatory perspective, packaging has gained a significant importance and need critical compliance. The packaging equipment market for pharmaceutical has evolved from conventional packaging systems to modern and automated system, and it is well on its way to further growth. Our study suggests that packaging equipment market for pharmaceutical is expected to grow at a healthy CAGR from 2013 to 2020.
    Aug 2016 | View Details >>
  • ...
    An Ostomy is a surgical procedure in which body wastes such as (urine, mucus and stools) are eliminated through an artificial opening from the colon of the human body, either to the outside surface or into a suitable organ. These wastes are collected in an artificial bags sited outside the patient’s body, called Ostomy Drainage Bags. These bags are used in the treatment of many diseases for instance-bladder, intestinal, inflammatory bowel diseases and many types of cancers.
    Aug 2016 | View Details >>
  • ...
    Pluripotent stem cells are embryonic stem cells that have the potential to form all adult cell types and help in repairing of damaged tissues in the human body. An induced pluripotent stem cells, or iPSCs, are taken from any tissue (usually skin or blood) from a child or an adult and is genetically modified to behave like pluripotent stem cells or embryonic stem cells.
    Aug 2016 | View Details >>
  • ...
    Spectrometry is an analytical technique that assists in the identification of compounds and elements. This identification is based on the measurement of radiant energy emitted by a substance when in a higher energy state. Spectrometry instruments play a vital role in the analytical, pharmaceutical and life science industry. These industries have witnessed a growing demand for spectrometric instruments as they form an integral part of basic research and are used in drug composition identification, identification of new compounds and metals and bimolecular analysis. Due to its significant applications in different industries,
    Aug 2016 | View Details >>